{"title":"[Treatment of hypertension syndrome of pregnancy with ligustrazine].","authors":"X H Qian, Y L Huang, S P Wu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>75 patients with hypertension syndrome of pregnancy (HSP) were randomly designed to 2 groups: the control group treated with magnesium sulfate (20-25g/d) and the Ligustrazine (120-160mg/d) group. The results of Ligustrazine group compared with the control group were as follows: (1) Mean arterial pressure was significantly decreased (P less than 0.01). (2) Edema and proteinuria was lowered (P less than 0.05). (3) The condition of rheology was improved, especially, hematocrit was significantly decreased (P less than 0.001). (4) The positive rate of NST and Apgar's score were not different between the 2 groups. Clinical monitoring showed Ligustrazine without side effects in the group. Mechanisms of Ligustrazine in HSP were (1) dilating blood vessel; (2) improving kidney function; (3) improving microcirculatory and rheology.</p>","PeriodicalId":23984,"journal":{"name":"Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine","volume":"11 9","pages":"533-4, 516"},"PeriodicalIF":0.0000,"publicationDate":"1991-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
75 patients with hypertension syndrome of pregnancy (HSP) were randomly designed to 2 groups: the control group treated with magnesium sulfate (20-25g/d) and the Ligustrazine (120-160mg/d) group. The results of Ligustrazine group compared with the control group were as follows: (1) Mean arterial pressure was significantly decreased (P less than 0.01). (2) Edema and proteinuria was lowered (P less than 0.05). (3) The condition of rheology was improved, especially, hematocrit was significantly decreased (P less than 0.001). (4) The positive rate of NST and Apgar's score were not different between the 2 groups. Clinical monitoring showed Ligustrazine without side effects in the group. Mechanisms of Ligustrazine in HSP were (1) dilating blood vessel; (2) improving kidney function; (3) improving microcirculatory and rheology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
